The international research & development consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis in patients who also are HIV-positive. The study will assess the efficacy and the safety of two treatments: a combination treatment of AmBisome- and miltefosine, and AmBisome- alone.
↧
AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients
↧